SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 14, 2023
GeneDx Holdings Corp.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
333 Ludlow Street, North Tower, 6th Floor
(Address of Principal Executive Offices)
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Class A common stock, par value $0.0001 per share||WGS||The Nasdaq Global Select Market|
|Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share||WGSWW||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition.
On March 14, 2023, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2022. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|GeneDx Holdings Corp.|
| Date:|| March 14, 2023||By:||/s/ Katherine Stueland|
|Title:||Chief Executive Officer|
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million
Completed financing in January 2023 with $150 million in expected proceeds; fully funded to expected profitability in 2025
GeneDx to host conference call today at 4:30 p.m. ET
STAMFORD, Conn., March 14, 2023 — GeneDx Holdings Corp. (Nasdaq: WGS) (“GeneDx” or the “Company”), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year ended December 31, 2022.
“Entering 2023 with a new corporate strategy and a focus on delivering profitable growth, our team is uniquely positioned to enable precision medicine by combining the power of scalable genomic sequence analysis with data from our Centrellis® platform,” said Katherine Stueland, Chief Executive Officer of GeneDx. “We have a significant opportunity to grow testing in pediatric rare disease, expand into the adult and newborn screening markets, and build our data information business. With our strong balance sheet following the successful closing of our recent public offering, we are fully funded through our expected profitability in 2025.”
Recent Business Highlights
•Announced name change to GeneDx Holdings Corp. and began trading under new ticker (Nasdaq: WGS) in January 2023
•Announced the closing of an underwritten public offering and concurrent registered direct offering for expected total gross proceeds of approximately $150 million in January 2023, including proceeds from the pending issuance of the additional shares in the direct offering
•Announced published research underscoring the role of genetic insights demonstrating how the study of rare disease can improve understanding of the biology of common disorders and can aid in the drug discovery and development process
•Announced presentations at the upcoming 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Full Year 2022 Business Highlights
•Completed acquisition of GeneDx, LLC (“Legacy GeneDx”) and corporate restructuring to focus on high growth and profitability by combining scalable exome and whole genome interpretation business with Centrellis® health insights platform
•Established new management team led by Katherine Stueland as Chief Executive Officer
•Announced partnership in GUARDIAN genomic newborn screening study, the largest of its kind in North America, to improve population health by identifying more than 250 preventable and treatable conditions
•Collaborated in research that demonstrated that the use of exome or genome sequencing results in a significantly lower rate of variants of uncertain significance (VUS) compared to panel-based testing, with 30% fewer inconclusive results; research presented at the 2022 American Society of Human Genetics (ASHG) Annual Meeting
•Presented results from Phase 1 of SeqFirst Study at the 2022 ASHG Annual Meeting, demonstrating broad utility of rapid whole genome sequencing for critically ill newborns
•Presented research on autism spectrum disorders (ASD) at the Child Neurology Society (CNS) 2022 annual meeting, underscoring the positive outcomes of exome analysis for individuals with ASD
•Presented results of study on mitochondrial diseases in newborns, supporting the addition of mitochondrial DNA testing to rapid exome sequencing to lead to earlier diagnosis and potential changes in clinical management
“During the fourth quarter, we saw strong momentum across the pro forma continuing operations of GeneDx, particularly in whole exome sequencing, with total volume and whole exome volume increasing by 25.8% and 18.8% year-over-year, respectively. Throughout 2022, the Company delivered strong growth, and expanded pro forma adjusted gross margins to 41% for the fourth quarter of 2022. We believe our strategy to target higher value areas of the genomics market is working, and in 2023 we intend to continue to execute on our plans to improve our operational efficiency and reduce our cash burn,” said Kevin Feeley, Chief Financial Officer of GeneDx.
In the discussion that follows, “Legacy Sema4” refers to the businesses of the Company excluding the Legacy GeneDx business, and the “now discontinued Legacy Sema4 diagnostic testing business” refers to reproductive and women’s health testing, which we exited during the first quarter of 2023, somatic tumor testing, which we exited in the fourth quarter of 2022, and COVID-19 testing, which we discontinued in the first quarter of 2022.
Sema4 and GeneDx Combined Company Fourth Quarter and Full Year Financial Results Including Now Discontinued Legacy Sema4 Diagnostic Testing Business1
Combined Company results reported today for the fourth quarter of 2022 include the combination of continuing operations and the now discontinued Legacy Sema4 diagnostic testing business, and total Company results for the full year 2022 include Legacy GeneDx and its revenues and costs only for the partial year period from the closing of the acquisition of Legacy GeneDx. Accordingly, combined Company results for 2021 do not include revenues or costs from Legacy GeneDx.
Combined Company revenue for the fourth quarter of 2022 was $61.4 million, compared to $57.8 million in the fourth quarter of 2021, representing an increase of 6.2%. Combined Company revenue for the full year of 2022 was $234.7 million, compared to $212.2 million in 2021, representing an increase of 10%.
Total Company gross margin for the fourth quarter of 2022 was (27)%, with an adjusted gross margin of 7%2 in the quarter. Total Company gross margin for the full year of 2022 was (11)%. Adjusted gross margin for the full year of 2022 was 5%2.
Total Company net operating loss for the fourth quarter of 2022 was ($324.8) million. Total Company adjusted net operating loss for the fourth quarter of 2022 was ($72.7) million2. Total Company net operating loss for the full year of 2022 was ($667.6) million. Total Company adjusted net operating loss for the full year of 2022 was ($326.0) million2.Total cash and cash equivalents and restricted cash were $138.3 million as of December 31, 2022.
GeneDx Pro Forma Fourth Quarter and Full Year Financial Results from Continuing Operations1
Pro forma results from continuing operations for GeneDx reported today include the combination of Legacy GeneDx and only the data and information business of Legacy Sema4, and assume Legacy GeneDx was owned for the entirety of 2022 and 2021. Continuing operations exclude revenues and costs from the now discontinued Legacy Sema4 disagnostics testing business.
Pro forma revenues from continuing operations for the fourth quarter of 2022 was $45.8 million, compared to $34.7 million in the fourth quarter of 2021, representing an increase of 32%. Pro forma revenues from continuing operations for the full year of 2022 was $171.0 million, compared to $123.7 million in 2021, representing an increase of 38%.
Pro forma adjusted gross margin from continuing operations in the fourth quarter of 2022 was 41%. Pro forma adjusted gross margin for the full year of 2022 was 39%2.
Full Year 2023 Guidance
GeneDx is reiterating its previously issued full year 2023 guidance.
The continuing operations of GeneDx, excluding revenues and direct costs from the now discontinued Legacy Sema4 diagnostic testing business, are expected to:
•Generate revenues between $205 to $220 million for full year 2023;
•Expand gross margin profile in 2023 and beyond;
•Use $95 to$110 million of net cash in 2023 for continuing operations. Inclusive of servicing obligations of the exited business activities, the Company’s cash burn in 2023 is expected to be in the range of $130 to $145 million; and
•Turn profitable in 2025.
1 The pro forma unadjusted and adjusted results from continuing operations for 2022 and the comparable results for 2021 are presented on a pro forma basis assuming Legacy GeneDx and the Company were combined for the entirety of 2021 and 2022 and exclude the revenues and costs from the now discontinued Legacy Sema4 diagnostic testing business, and include the combination of the Legacy GeneDx diagnostic business revenues and costs with the data and information revenues and associated costs derived from the Legacy Sema4 business. Actual total Company results include the results of the Legacy GeneDx business only from the date of the Company’s acquisition of Legacy GeneDx on April 29, 2022, the purchase accounting associated with the acquisition of Legacy GeneDx, and also include the financial impacts of exited Legacy Sema4 business activities for the full year.
2 Adjusted gross margin and adjusted net loss are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.
Webcast and Conference Call Details
GeneDx will host a conference call today, March 14, 2023, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and our market opportunity, including our expected full year 2023 reported revenue guidance, our expectations regarding our gross margin profile in 2023 and beyond, our use of cash for continuing operations and our cash burn in 2023 and our turning profitable in 2025, our expectations for our growth and future investment in our business, our expectations regarding our plans to pursue new strategic direction, improve our operational efficiency and reduce our cash burn and our ability to scale to profitability, the associated cost savings of our business exits and impact on our gross margins. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) our ability to pursue our new strategic direction. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 14, 2022, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
Investor Relations Contact:
Pro forma select volume and revenue from Continuing Operations in the table below assumes Legacy GeneDx was owned for the entirety of the applicable quarter(s) and are calculated based on the construct of our continuing operations inclusive of Legacy GeneDx combined with data revenues and associated costs from Legacy Sema4. Pro forma select metrics are presented for illustrative purposes only and are not necessarily indicative of the results that would have occurred had the GeneDx acquisition been completed on such dates or that may occur in the future.
Pro Forma Select GeneDx Volume & Revenue from Continuing Operations
|Volumes|| || || || || |
|Whole Exome, Whole Genome||6,619||7,397||7,579||7,722||7,862|
|Exome based Panels||2,725||2,630||3,141||2,983||3,013|
|Other individual gene tests and multi-gene disease panels||25,550||24,610||27,446||28,764||31,891|
| || || || || |
|Revenue|| || || || || |
|Whole Exome, Whole Genome||$15.3||$18.4||$21.1||$24.0||$23.3|
|Exome based Panels||$1.9||$2.4||$2.4||$2.3||$2.0|
|Other individual gene tests and multi-gene disease panels||$12.4||$12.8||$10.5||$15.6||$14.3|
Unaudited Pro forma select financial information assume Legacy GeneDx was owned for the entirety of the year and is calculated based on the construct of our continuing operations inclusive of Legacy GeneDx combined with data revenues and associated costs from Legacy Sema4. Unaudited Pro forma select financial information is presented for illustrative purposes only and are not necessarily indicative of the results that would have occurred had the Legacy GeneDx acquisition been completed on such dates or that may occur in the future.
UNAUDITED PRO FORMA SELECT FINANCIAL INFORMATION
FOR THE THREE MONTHS ENDED DECEMBER 31, 2022
|GeneDx Continuing Operations||Legacy Sema4 Discontinued Business||Combined GeneDx and Sema|
|Adjusted Cost of Services||27,000||30,093||57,093|
|Adjusted Gross Margin||18,824||(14,566)||4,257|
|Adjusted Gross Margin %||41.6%||(93.8)%||6.9%|
UNAUDITED PRO FORMA SELECT FINANCIAL INFORMATION
FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2022
|GeneDx Continuing Operations||Legacy Sema4 Discontinued Business||Combined GeneDx and Sema4|
|Adjusted Cost of Services||103,962||147,868||251,831|
|Adjusted Gross Margin||67,080||(35,412)||31,668|
|Adjusted Gross Margin %||39.2%||(31.5)%||11.2%|
Total Company results below for the fourth quarter of 2022 include the combination of continuing operations and the now discontinued Legacy Sema4 diagnostic testing business, and Total Company results for the full year 2022 include Legacy GeneDx and its revenues and costs only for the partial year period since the time of acquisition. Accordingly, Total Company results for 2021 do not include revenues or costs from Legacy GeneDx.
GeneDx Holdings Corp.
Reconciliation of Revenue to Adjusted Gross Margin & Adjusted Operating Loss
(unaudited, in thousands)
| ||Three Months Ended December 31,|| ||Year Ended December 31,|
| ||2022|| ||2022|
| ||(in thousands)|| ||(in thousands) |
|Revenue|| || || |
|Diagnostic test revenue||59,344|| ||227,334|
|Other Revenue||2,006|| ||7,361|
|Total Revenue||61,350|| ||234,694|
|Cost of Service||77,676|| ||261,444|
|Gross (Loss) Profit||(16,326)|| ||(26,750)|
|Gross Margin||(27)%|| ||(11)%|
| || || || |
|Depreciation and Amortization||19,994|| ||31,328|
|Stock-based compensation||412|| ||5,080|
|Restructuring costs||177|| ||1,926|
|Adjusted Gross (Loss) Profit||4,257|| ||11,585|
|Adjusted Gross Margin||7%|| ||5%|
| || || || |
|Research & Development||24,366|| ||86,203|
|Depreciation and Amortization||9,150|| ||14,960|
|Stock-based compensation||(937)|| ||1,755|
|Restructuring costs||966|| ||3,260|
|Adjusted Research & Development||15,187|| ||66,227|
| || || || |
|Selling & Marketing||31,797|| ||134,913|
|Depreciation and Amortization||1,226|| ||3,271|
|Stock-based compensation||(149)|| ||6,498|
|Restructuring costs||3,272|| ||7,979|
|Adjusted Selling & Marketing||27,448|| ||117,166|
| || || || |
|General & Administrative & Related Party Expense||42,249|| ||209,642|
|Depreciation and Amortization||3,670|| ||9,749|
|Stock-based compensation||1,096|| ||28,642|
|Restructuring costs||1,532|| ||11,570|
|Transaction and acquisition costs||1,588|| ||5,439|
|Adjusted General & Administrative & Related Party||34,362|| ||154,241|
| || || || |
|Total Adjusted Operating Expenses||76,998|| ||337,634|
| || || || |
|Impairment Loss||210,145|| ||210,145|
| || || || |
|Loss from Operations||(324,883)|| ||(667,652)|
|Depreciation and Amortization||34,040|| ||59,309|
|Stock-based compensation||423|| ||41,976|
|Restructuring costs||5,947|| ||24,735|
|Transaction and acquisition costs||1,588|| ||5,439|
|Impairment Loss||210,145|| ||210,145|
|Adjusted loss from operations||(72,740)|| ||(326,049)|
The financial statements that follow represents our preliminary unaudited consolidated financial statements, for the year ended December 31, 2022, subject to change, which have been prepared in accordance with U.S. GAAP. Results include the combination of Legacy GeneDx and Legacy Sema4 with the activities of Legacy GeneDx only from the time of acquisition.
GeneDx Holdings Corp.
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
|Cash and cash equivalents||$ 123,933||$ 400,569|
|Accounts receivable, net||42,634||26,509|
|Due from related parties||708||54|
|Other current assets||6,390||3,802|
|Total current assets||212,622||483,544|
|Property and equipment, net||51,527||62,719|
|Intangible assets, net||186,650||—|
|Operating lease right-of-use assets||32,758||—|
|Long-term restricted cash||900||900|
|Total assets||$ 490,942||$ 554,093|
Liabilities and Stockholders’ Equity
|Accounts payable||$ 46,017||$ 44,693|
|Due to related parties||3,593||2,623|
|Current portion of lease liabilities||6,121||—|
|Other current liabilities||49,665||33,387|
|Total current liabilities||144,297||101,284|
|Long-term debt, net of current portion||6,250||11,000|
|Long-term lease liabilities||60,013||—|
|Earn-out contingent liability||1,600||10,244|
|Commitments and contingencies (Note 10)|
Preferred Stock, $0.0001 par value: 1,000,000 shares authorized at December 31, 2022 and December 31, 2021; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively
Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 388,511,138 shares issued and outstanding at December 31, 2022 and $0.0001 par value: 380,000,000 shares authorized, 242,647,604 shares issued and outstanding at December 31, 2021
|Additional paid-in capital||1,378,088||963,520|
|Total stockholders’ equity||253,705||388,103|
Total liabilities and stockholders’ equity
|$ 490,942||$ 554,093|
GeneDx Holdings Corp.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share and share amounts)
|Year Ended December 31,|
|2022||2021 Audited||2020 Audited|
|Diagnostic test revenue||$ 227,334||$ 205,100||$ 175,351|
Cost of services
|Gross (loss) profit||(26,750)||(16,602)||4,026|
|Research and development||86,203||105,162||72,700|
|Selling and marketing||134,913||112,738||63,183|
|General and administrative||203,329||205,988||100,742|
|Related party expenses||6,312||5,659||9,395|
|Loss from operations||(667,652)||(446,149)||(241,994)|
|Other income (expense):|
|Change in fair market value of warrant and earn-out contingent liabilities||70,229||198,401||—|
|Other income, net||57||5,114||2,622|
|Total other income, net||69,620||200,759||654|
|Loss before income taxes||(598,032)||(245,390)||(241,340)|
|Income tax benefit||49,052||—||—|
|Net loss and comprehensive loss||$ (548,980)||$ (245,390)||$ (241,340)|
|Weighted average shares outstanding, Class A common stock||337,819,680||108,077,439||5,131|
|Basic and diluted net loss per share, Class A common stock||(1.63)||(2.27)||(47,036)|
GeneDx Holdings Corp.
Consolidated Statements of Cash Flows
|Year Ended December 31,|
|2022||2021 Audited||2020 Audited|
|Net loss||$ (548,980)||$ (245,390)||$ (241,340)|
Adjustments to reconcile net loss to net cash used in operating activities:
|Depreciation and amortization expense||59,309||21,807||11,734|
|Stock-based compensation expense||41,975||219,421||120,231|
|Change in fair value of warrant and contingent liabilities||(70,229)||(198,401)||—|
|Income tax benefit||(49,124)||—||—||—|
|Provision for excess and obsolete inventory||(1,125)||2,129||—|
|Non-cash lease expense||2,225||1,555||2,400|
|Loss on extinguishment of debt||—||301||—|
|Amortization of debt issuance costs||518||66||—|
|Change in operating assets and liabilities, net of effects from purchase of business:|
|Prepaid expenses and other current assets||11,130||(14,250)||2,498|
|Due to/from related parties||317||1,433||(442)|
|Accounts payable and accrued expenses||34,459||25,916||14,805|
|Other current liabilities||(19,467)||3,239||15,960|
|Net cash used in operating activities||$ (319,155)||$ (190,434)||$ (93,128)|
|Purchase of business, net of cash acquired||$ (127,004)||$ —||$ —|
|Purchases of property and equipment||(7,156)||(9,400)||(24,094)|
|Development of internal-use software assets||(7,166)||(11,386)||(7,880)|
|Net cash used in investing activities||$ (141,326)||$ (20,786)||$ (31,974)|
Proceeds from issuance of Series C redeemable convertible preferred stock, net of issuance costs
|$ —||$ —||$ 117,324|
|Proceeds from PIPE issuance||197,659||350,000||—|
|Proceeds from equity infusion from the merger, net of redemptions||—||442,684||—|
|Legacy Sema4 Shareholder payout||—||(230,665)||—|
|Payment of transaction costs||—||(51,760)||—|
|Stock Appreciation Rights payout||—||(3,795)||—|
|Repayment of long-term debt||—||(8,741)||—|
|Exercise of stock options||2,948||1,271||—|
|Proceeds from long-term debt||—||—||15,928|
|Long-term debt principal payments||—||(1,000)||(186)|
|Debt issuance costs||—||(537)||—|
|Finance lease principal payments||(3,292)||(3,728)||(4,010)|
|Net cash provided by financing activities||$ 197,315||$ 493,729||$ 129,056|
Net (decrease) increase in cash, cash equivalents and restricted cash
|$ (263,166)||$ 282,509||$ 3,954|
|Cash, cash equivalents and restricted cash, at beginning of year||401,469||118,960||115,006|
|Cash, cash equivalents and restricted cash, at end of year||$ 138,303||$ 401,469||$ 118,960|
March 14, 2023 One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 4Q and Year End 2022 Earnings Presentation
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements about: our future performance and our market opportunity our expected full year 2023 reported revenue guidance, our expectations regarding our gross margin profile in 2023 and beyond, our use of cash for continuing operations and our cash burn in 2023 and our turning profitable in 2025, our expectations for our growth and future investment in our business, our expectations regarding our plans to pursue a new strategic direction, improve our operational efficiency and reduce our cash burn and our ability to scale to profitability, the associated cost savings of our business exits and impact on our gross margins.. We cannot assure that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward- looking statements prove to be inaccurate, the inaccuracy may be material. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this presentation are based on our management’s beliefs and assumptions and are based upon information currently available to our management as of the date of this presentation and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation, including but not limited to: (i) the ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) our ability to pursue our new strategic direction. The information, opinions and forward- looking statements contained in this announcement speak only as of its date and are subject to change without notice Use of Non-GAAP Financial Measures This presentation includes non-GAAP financial measures, including Adjusted Gross Profit (Loss), Adjusted Gross Margin and Adjusted EBITDA. We define Adjusted Gross Profit (Loss) as revenue less cost of services, excluding stock-based compensation expense and restructuring costs, and we define Adjusted Gross Margin as our Adjusted Gross Profit (Loss) divided by our revenue. We define Adjusted EBITDA as our net loss adjusted for interest expense, net, income tax expense, depreciation and amortization, stock-based compensation expense, transaction, acquisition and business integration costs, restructuring costs, change in fair market value of financial liabilities and other income. Management believes that these non-GAAP measures of financial results are useful in evaluating the GeneDx's operating performance compared to that of other companies in its industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. This presentation contains estimates, projections and other information concerning our industry, our business, and the markets for our products and services. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports and other filings we make with the SEC from time to time. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us are available www.sec.gov. Requests for copies of such documents should be directed to our Investor Relations department at GeneDx Holdings Corp. 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut, 06902. Our telephone number is 800-298-6470.
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
The problem: lack of genomic data and connectivity with EMR Symptoms Tests are ordered More tests But no answers Try new doctors But no records Suboptimal care Waiting for answers that come too late Patients miss milestones Waiting for a proper diagnosis More tests And more spending Years of missed diagnosis leads to: • Inappropriate treatments • Increased costs on the healthcare system • Suffering for patients and families • Stress on providers • Missed opportunities to develop treatments and solutions
Our Solution: Genomic Data + Clinical Insights = Better Health
>400K clinical exomes > 1 million DNA extractions >400 gene discovery publications Built by GeneDx: Genomic interpretation platform Since our inception more than 20 years ago, we believe we offer the most definitive genomic analysis in the industry, borne from over a decade of constructing our proprietary data sets Invested in: • Scalable genome lab and informatics • New commercial strategy and team • Medical affairs and managed care >2.7 million phenotypes
Built by Sema4: Centrellis health insights platform We’ve spent over 10 years developing the most sophisticated dataset in the industry, complete with custom algorithms and more accurate analyses 3.1 million patient health records 8 million disease diagnoses 47 million phenotypes 20 years of records abstracted from 56 million clinical documents • Strengthening data asset for Centrellis • Reorganized product and technology team for scale • Discontinued reproductive health, somatic oncology, commercial operations
Best of both creates a seamless solution Sequence once Expand the use of and deliver best in class whole exome/genome analysis & interpretation Combine clinical + genomic data Match structured clinical and genomic data and supplement with disease models to drive insights Providing actionable insights - Leveraging clinical data adds a critical layer onto what we know from structured genomic data including, phenotypic information, symptoms, family history, and longitudinal data Centrellis® Generate genomic insights over time Generate patient-specific and disease profiles to generate actionable reports upon presentation of symptoms
4Q 2022 and Recent Highlights 9 Completed strategic shift to focus on scalable business and profitable growth $138.2M in cash, cash equivalents and restricted cash as of 12/31/22; fully funded to expected profitability in 2025 Completed financing in January 2023 with $150 million in expected proceeds Financial results are in line with previously announced preliminary 2022 results; reiterating 2023 guidance
Strong Momentum Across Pro Forma Legacy GeneDx Volume & Revenue 10 Full Year 2022 Volume Mix Full Year 2022 Revenue Mix1 ~49k tests Q4 total volume +26% YoY1 7,862 Q4 Whole Exome / Whole Genome tests +19% YoY $45.8M Q4 total revenue +31% YoY1 $171.0M 2022 total revenue 39% adj gross margin $171.0M 2022 total revenue 39% adj gross margin 1 The pro forma unadjusted and adjusted results from continuing operations for 2022 and the comparable results for 2021 are presented on a pro forma basis assuming Legacy GeneDx and the Company were combined for the entirety of 2021 and 2022 and exclude the revenues and costs from the now discontinued reproductive health, somatic tumor and COVID-19 testing businesses, and include the combination of the Legacy GeneDx diagnostic business revenues and costs with the data and information revenues and associated costs derived from the Legacy Sema4 business. Actual total Company results include the results of the Legacy GeneDx business only from the date of the Company’s acquisition of Legacy GeneDx on April 29, 2022, the purchase accounting associated with the acquisition of Legacy GeneDx, and also include the financial impacts of exited Legacy Sema4 business activities for the full year. Pro forma metrics are presented for illustrative purposes only and are not necessarily indicative of the results th t would have occurred had the Legacy GeneDx acquisition been completed on such dates or that may occur in the future. WES/WGS 17% Exome Based 7% Hereditary Cancer 14% Other Tests 62% WES/WGS 53% Exome Based 6% Hereditary Cancer 9% Other Tests 32%
v Revenues between $205-220 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-145 million, a >50% reduction year-over-year Use of net $95-110 million in cash in 2023 for continuing operations Turn to profitability in 2025 2023 Guidance